Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-213931 · Präparat HOS-155234
5
Table 1: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL
PRODUCTS
Medicinal products by Interaction Recommendations concerning
therapeutic areas Geometric mean change (%) co-administration
ANTI-INFECTIVES
Antiretrovirals
HIV NRTIs/N[t]RTIs
Didanosine*# didanosine AUC ↑ 12% No dose adjustment is required.
400 mg once daily didanosine Cmin NA Didanosine should be administered at
didanosine Cmax ↔ least two hours before or at least four
rilpivirine AUC ↔ hours after rilpivirine.
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Tenofovir disoproxil *# tenofovir AUC ↑ 23% No dose adjustment is required.
245 mg once daily tenofovir Cmin ↑ 24%
tenofovir Cmax ↑ 19%
rilpivirine AUC ↔
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Other NRTIs Not studied. No clinically relevant No dose adjustment is required.
(abacavir, emtricitabine, drug-drug interactions are expected.
lamivudine, stavudine
and zidovudine)
HIV NNRTIs
NNRTIs Not studied. It is not recommended to
(delavirdine, efavirenz, co-administer rilpivirine with other
etravirine, nevirapine) NNRTIs.
HIV PIs – with co-administration of low dose ritonavir
Darunavir/ritonavir*# darunavir AUC ↔ Concomitant use of rilpivirine with
800/100 mg once daily darunavir Cmin ↓ 11% ritonavir-boosted PIs causes an
darunavir Cmax ↔ increase in the plasma concentrations
rilpivirine AUC ↑ 130% of rilpivirine, but no dose adjustment
rilpivirine Cmin ↑ 178% is required.
rilpivirine Cmax ↑ 79%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) darunavir (HOS-086181) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage e6d1aeb7ba2f265a48a0f9e4bedfdb523c00ec0b8a0eab1f7f1643ca7f5bebb4 · Zeichen 2025–4372 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-213998 · Präparat HOS-155234
Table 2: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL
PRODUCTS
Medicinal products by Interaction Recommendations concerning
therapeutic areas Geometric mean change (%) co-administration
ANTI-INFECTIVES
Antiretrovirals
HIV NRTIs/N[t]RTIs
Didanosine*# didanosine AUC ↑ 12% No dose adjustment is required.
400 mg once daily didanosine Cmin NA Didanosine should be administered at
didanosine Cmax ↔ least two hours before or at least four
rilpivirine AUC ↔ hours after rilpivirine.
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Tenofovir disoproxil *# tenofovir AUC ↑ 23% No dose adjustment is required.
245 mg once daily tenofovir Cmin ↑ 24%
tenofovir Cmax ↑ 19%
rilpivirine AUC ↔
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Other NRTIs Not studied. No clinically relevant No dose adjustment is required.
(abacavir, emtricitabine, drug-drug interactions are expected.
lamivudine, stavudine
and zidovudine)
HIV NNRTIs
NNRTIs Not studied. It is not recommended to
(delavirdine, efavirenz, co-administer rilpivirine with other
etravirine, nevirapine) NNRTIs.
HIV PIs – with co-administration of low dose ritonavir
Darunavir/ritonavir*# darunavir AUC ↔ Concomitant use of rilpivirine with
800/100 mg once daily darunavir Cmin ↓ 11% ritonavir-boosted PIs causes an
darunavir Cmax ↔ increase in the plasma concentrations
rilpivirine AUC ↑ 130% of rilpivirine, but no dose adjustment
rilpivirine Cmin ↑ 178% is required.
rilpivirine Cmax ↑ 79%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) stavudine (HOS-088080) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) darunavir (HOS-086181) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) ritonavir (HOS-084521) abacavir (HOS-088077) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage f8d4cdaee0bf44e65f98cc6e120db4b6262a184b4f650e2f7b5c77fb0d2e65b4 · Zeichen 2027–4403 im Abschnitt
Wechselwirkungen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-214359 · Präparat HOS-155326
Didanosine
The co-administration of Eviplera and didanosine is not recommended (see section 4.4 and Table 1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage f2e983a43786439869b8036a0e1a08d8fce8f6c0b4fd82a7fb0cc0fb0783dc6a · Zeichen 1535–1644 im Abschnitt
Wechselwirkungen · Eviplera
Eviplera 200 mg/25 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-214376 · Präparat HOS-155326
Medicinal product by therapeutic Effects on medicinal product Recommendation concerning
areas levels. co-administration with Eviplera
Mean percent change in AUC,
Cmax, Cmin
ANTI-INFECTIVES
Antiretrovirals
Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs/N[t]RTIs)
Didanosine/Emtricitabine Interaction not studied. Co-administration of Eviplera and
Didanosine (400 mg once daily)/ Didanosine: didanosine is not recommended
Rilpivirine1 AUC: ↑ 12% (see section 4.4).
Cmin: N/A
Cmax: ↔ Increased systemic exposure to
didanosine may increase
Rilpivirine: didanosine related adverse
AUC: ↔ reactions. Rarely, pancreatitis and
Cmin: ↔ lactic acidosis, sometimes fatal,
Cmax: ↔ have been reported.
Didanosine/Tenofovir disoproxil Co-administration of tenofovir Co-administration of tenofovir
disoproxil and didanosine results in disoproxil and didanosine at a dose
a 40-60% increase in systemic of 400 mg daily has been
exposure to didanosine. associated with a significant
decrease in CD4+ cell count,
possibly due to an intracellular
interaction increasing
phosphorylated (i.e. active)
didanosine. A decreased dosage of
250 mg didanosine
co-administered with tenofovir
disoproxil therapy has been
associated with reports of high
rates of virological failure within
several tested combinations for the
treatment of HIV-1 infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-06-19T11:57:00Z · SHA-256 3873fd554f54608c25be65a5e155834d2d4981603221b5f24abb68e92e1af40e · Passage d3a0fdaec6ddf8271b55ed9ab603c107deca4d7dd08df76423b27023b5c7d161 · Zeichen 4134–7211 im Abschnitt
Wechselwirkungen · Stribild
Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-218464 · Präparat HOS-216207
13
Medicinal product by therapeutic Effects on drug levels Recommendation concerning
areas Mean percent change in AUC, Cmax, co-administration with Stribild
Cmin1
Nucleoside reverse transcriptase inhibitors (NRTIs)
Didanosine Co-administration of tenofovir Co-administration of Stribild and
disoproxil and didanosine results in a didanosine is not recommended.
40-60% increase in systemic exposure
to didanosine. Increased systemic exposure to
didanosine may increase didanosine
related adverse reactions. Rarely,
pancreatitis and lactic acidosis,
sometimes fatal, have been
reported. Co-administration of
tenofovir disoproxil and didanosine
at a dose of 400 mg daily has been
associated with a significant
decrease in CD4 cell count,
possibly due to an intracellular
interaction increasing
phosphorylated (i.e. active)
didanosine. A decreased dosage of
250 mg didanosine co-administered
with tenofovir disoproxil therapy
has been associated with reports of
high rates of virological failure
within several tested combinations
for the treatment of
HIV-1 infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-23T16:51:00Z · SHA-256 d3f228ded6370d77784fda3a53beaff9f1155c63df0f682c7673ee3cdc2ccdc5 · Passage b2fa71d83928e7ba7c689d1bf748573abe9da137080213d482cdbada44edd3cb · Zeichen 17396–20312 im Abschnitt
Wechselwirkungen · Stribild
Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-218466 · Präparat HOS-216207
However, in case of initiation of
Stribild in patients previously
taking didanosine or
discontinuation of Stribild and
change to a regimen including
didanosine there could be a short
period when measurable plasma
levels of didanosine and tenofovir
occur.
Macrolide antibiotics
Clarithromycin Interaction not studied with any of the No dose adjustment of
components of Stribild. clarithromycin is required for
patients with normal renal function
Concentrations of clarithromycin and/or or mild renal impairment (ClCr
cobicistat may be altered with 60-90 mL/min). Clinical
co-administration of Stribild. monitoring is recommended for
patients with ClCr < 90 mL/min.
For patients with ClCr
< 60 mL/min, alternative
antibacterials should be considered.
Telithromycin Interaction not studied with any of the Clinical monitoring is
components of Stribild. recommended upon
co-administration of Stribild.
Concentrations of telithromycin and/or
cobicistat may be altered with
co-administration of Stribild.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) telithromycin (HOS-084523) clarithromycin (HOS-084517) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-23T16:51:00Z · SHA-256 d3f228ded6370d77784fda3a53beaff9f1155c63df0f682c7673ee3cdc2ccdc5 · Passage b23dcb95b90fa7ad81e13c3ad0e3943f3e409791e987bb3b74b77d88da863fff · Zeichen 20392–22877 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-129249 · Präparat HOS-096703
Emtricitabine, didanosine, Interaction not studied Triumeq is not recommended for use in
stavudine, zidovudine. combination with emtricitabine
containing products, since both
lamivudine (in Triumeq) and
emtricitabine are cytidine analogues (i.e.
risk for intracellular interactions, (see
section 4.4))
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir ↑ No dose adjustment is necessary.
AUC ↑ 91%
Cmax ↑ 50%
Cτ ↑ 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) stavudine (HOS-088080) didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 3bf10bb4dbff2b9e9a1f2913477a1a9b99c0f91eb5eef71b2dcdb54e9afc81f8 · Zeichen 10865–11769 im Abschnitt
Wechselwirkungen · Triumeq
Triumeq 5 mg/60 mg/30 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 47
HOS-129348 · Präparat HOS-096703
Emtricitabine, didanosine, Interaction not studied Triumeq is not recommended for use in
stavudine, zidovudine. combination with emtricitabine
containing products, since both
lamivudine (in Triumeq) and
emtricitabine are cytidine analogues (i.e.
risk for intracellular interactions, (see
section 4.4))
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir ↑ No dose adjustment is necessary.
AUC ↑ 91%
Cmax ↑ 50%
Cτ ↑ 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) stavudine (HOS-088080) didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 3bf10bb4dbff2b9e9a1f2913477a1a9b99c0f91eb5eef71b2dcdb54e9afc81f8 · Zeichen 9175–10079 im Abschnitt
Wechselwirkungen · Rezolsta
REZOLSTA 800 mg/150 mg film-coated tablets REZOLSTA 675 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-220454 · Präparat HOS-216626
Table 1 Interactions and dose recommendations with other medicinal products
Medicinal product examples by Interaction Recommendations concerning
therapeutic area co-administration
HIV ANTIRETROVIRALS
Integrase strand transfer inhibitors
Dolutegravir Based on theoretical REZOLSTA and dolutegravir can
considerations dolutegravir is not be used without dose
expected to affect the adjustments.
pharmacokinetics of REZOLSTA.
Raltegravir Some clinical trials suggest At present the effect of
raltegravir may cause a modest raltegravir on darunavir plasma
decrease in darunavir plasma concentrations does not appear to
concentrations. be clinically relevant;
REZOLSTA and raltegravir can
be used without dose
adjustments.
HIV Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine No mechanistic interaction REZOLSTA and didanosine can
400 mg once daily expected based on theoretical be used without dose
consideration. adjustments.
When didanosine is
co-administered with
REZOLSTA, didanosine should
be administered on an empty
stomach 1 hour before or 2 hours
after REZOLSTA (which is
administered with food).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dolutegravir (HOS-089992) didanosine (HOS-085836) raltegravir (HOS-086187)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T17:33:00Z · SHA-256 fd4a09675891eba65ab2ce0a1cb84ffd3afbb1ff64ec7131830fe2eae67d87dc · Passage c78f23a4daa89654bd65555888203497cf939b66a255a513a01a29dec30ee4b2 · Zeichen 4014–6417 im Abschnitt
Wechselwirkungen · Rezolsta
REZOLSTA 600 mg/90 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 43–44
HOS-220553 · Präparat HOS-216626
43
Table 1 Interactions and dose recommendations with other medicinal products
Medicinal product examples by Interaction Recommendations concerning
therapeutic area co-administration
HIV ANTIRETROVIRALS
Integrase strand transfer inhibitors
Dolutegravir Based on theoretical REZOLSTA and dolutegravir can
considerations dolutegravir is not be used without dose
expected to affect the adjustments.
pharmacokinetics of REZOLSTA.
Raltegravir Some clinical trials suggest At present the effect of
raltegravir may cause a modest raltegravir on darunavir plasma
decrease in darunavir plasma concentrations does not appear to
concentrations. be clinically relevant;
REZOLSTA and raltegravir can
be used without dose
adjustments.
HIV Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine No mechanistic interaction REZOLSTA and didanosine can
400 mg once daily expected based on theoretical be used without dose
consideration. adjustments.
When didanosine is
co-administered with
REZOLSTA, didanosine should
be administered on an empty
stomach 1 hour before or 2 hours
after REZOLSTA (which is
administered with food).
Tenofovir disoproxil * Based on theoretical REZOLSTA and tenofovir
considerations REZOLSTA is disoproxil can be used without
*study was done with tenofovir expected to increase tenofovir dose adjustments.
disoproxil fumarate plasma concentrations. Monitoring of renal function may
(P-glycoprotein inhibition) be indicated when REZOLSTA is
given in combination with
tenofovir disoproxil, particularly
in patients with underlying
systemic or renal disease, or in
patients taking nephrotoxic
agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of F/TAF
alafenamide (F/TAF) Tenofovir ↑ is 200/10 mg once daily when
used with REZOLSTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir alafenamide (HOS-110476) dolutegravir (HOS-089992) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) raltegravir (HOS-086187) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T17:33:00Z · SHA-256 fd4a09675891eba65ab2ce0a1cb84ffd3afbb1ff64ec7131830fe2eae67d87dc · Passage 217e3ede3b97e75ba92eab4ced6dfb1e1a2ba876cf83232f66b65de025e32f9f · Zeichen 4068–7829 im Abschnitt
Wechselwirkungen · Lonsurf
Lonsurf 15 mg/6.14 mg film-coated tablets Lonsurf 20 mg/8.19 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-221291 · Präparat HOS-216824
Caution is required when using medicinal products that are human thymidine kinase substrates, e.g.,
zidovudine. Such medicinal products, if used concomitantly with Lonsurf, may compete with the
effector, trifluridine, for activation via thymidine kinases. Therefore, when using antiviral medicinal
products that are human thymidine kinase substrates, monitor for possible decreased efficacy of the
antiviral medicinal product, and consider switching to an alternative antiviral medicinal product that is
not a human thymidine kinase substrate, such as lamivudine, didanosine and abacavir (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-09-11T02:00:00Z · SHA-256 990f764265f4f9669b99b551ce90d01e8c1bf13122b232bfa56abc6ba84d63c6 · Passage 9fa8814843e7f6641ba77dd1b8fb9ba25642fb1a144d2643135e0c868a51dd70 · Zeichen 723–1329 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-221562 · Präparat HOS-216856
11
Medicinal products by Interaction Recommendations concerning
therapeutic area co-administration
ANTI-RETROVIRALS
Protease inhibitors: EVOTAZ in combination with other protease inhibitors is not recommended because
co-administration may not provide adequate protease inhibitor exposure.
indinavir Indinavir is associated with Co-administration of EVOTAZ
indirect unconjugated and indinavir is not recommended
hyperbilirubinaemia due to (see section 4.4).
inhibition of UGT.
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
lamivudine 150 mg twice daily + No significant effect on Based on these data and because
zidovudine 300 mg twice daily lamivudine and zidovudine cobicistat is not expected to have
(atazanavir 400 mg once daily) concentrations was observed a significant impact on the
when co-administered with pharmacokinetics of NRTIs, the
atazanavir. co-administration of EVOTAZ
with these medicinal products is
not expected to significantly alter
the exposure of the
co-administered medicinal
products.
didanosine (buffered tablets) atazanavir, simultaneous Didanosine should be taken in the
200 mg/stavudine 40 mg, both administration with ddI+d4T fasted state 2 hours after
single dose (fasted) EVOTAZ taken with food. The
(atazanavir 400 mg single dose) atazanavir AUC ↓87% (↓92% co-administration of EVOTAZ
↓79%) with stavudine is not expected to
atazanavir Cmax ↓89% (↓94% significantly alter the exposure of
↓82%) stavudine.
atazanavir Cmin ↓84% (↓90%
↓73%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) protease (HOS-085623) stavudine (HOS-088080) lamivudine (HOS-085829) didanosine (HOS-085836) zidovudine (HOS-085837)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage c854d4d4be88536c9e82ede72111cd80720468d6472557e670364865780effcb · Zeichen 11931–14533 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-221564 · Präparat HOS-216856
Atazanavir concentrations were
greatly decreased when
co-administered with didanosine
(buffered tablets) and stavudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage abdbe5a9447d347c7515eb3e130db331a89ab42967ba97a61f3eb962b40b9893 · Zeichen 15011–15241 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-221565 · Präparat HOS-216856
The mechanism of interaction is
a reduced solubility of atazanavir
with increasing pH related to the
presence of anti-acid agent in
didanosine buffered tablets.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 4657c0451e7f9ef9298cf86fa1f6910f1fc2e80f84408db6b78bfed0711b8994 · Zeichen 15280–15588 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-221566 · Präparat HOS-216856
No significant effect on
didanosine and stavudine
concentrations was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 8b1c669bc291dcda9e44f65fa3559b38b69d74e869fd2152a457a3f48aece2c9 · Zeichen 15627–15779 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-221567 · Präparat HOS-216856
12
Medicinal products by Interaction Recommendations concerning
therapeutic area co-administration
didanosine (enteric-coated didanosine (with food)
capsules) 400 mg single dose didanosine AUC ↓34% (↓40%
(atazanavir 400 mg once daily) ↓26%)
didanosine Cmax ↓36% (↓45%
↓26%)
didanosine Cmin ↑13% (↓9%
↑41%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage e8e3866745876e48435321d985fb811f3b9f8878d7ee4843fa927dc1237049a4 · Zeichen 15834–16389 im Abschnitt
Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-221568 · Präparat HOS-216856
No significant effect on
atazanavir concentrations was
observed when administered with
enteric-coated didanosine, but
administration with food
decreased didanosine
concentrations.
tenofovir disoproxil fumarate atazanavir AUC ↓25% (↓30% Tenofovir DF may decrease the
(tenofovir DF) 300 mg ↓19%) AUC and Cmin of atazanavir.
once daily atazanavir Cmax ↓21% (↓27% When co-administered with
(atazanavir 400 mg once daily) ↓14%) tenofovir DF, it is recommended
atazanavir Cmin ↓40% (↓48% that EVOTAZ and tenofovir DF
300 mg tenofovir disoproxil ↓32%) 300 mg be given together with
fumarate is equivalent to 245 mg food. Atazanavir increases
tenofovir disoproxil. tenofovir: tenofovir concentrations. Higher
AUC: ↑24% (↑21% ↑28%) concentrations could potentiate
Cmax: ↑14% (↑8% ↑20%) tenofovir-associated adverse
Cmin: ↑22% (↑15% ↑30%) reactions, including renal
disorders. Patients receiving
Co-administration of tenofovir tenofovir disoproxil should be
DF with cobicistat is expected to monitored for
increase tenofovir plasma tenofovir-associated adverse
concentrations. reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 76f7f9f780058fb7b3730329e89a27fd9b7ac86199ce52ab9bf13a189c139d86 · Zeichen 16426–18389 im Abschnitt
Wechselwirkungen · Atazanavir Viatris (previously Atazanavir Mylan)
Atazanavir Viatris 150 mg hard capsules Atazanavir Viatris 200 mg hard capsules Atazanavir Viatris 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-223176 · Präparat HOS-217134
11
Medicinal products by Interaction Recommendations
therapeutic area concerning co-
administration
medicinal products and
atazanavir is not
expected to significantly
alter the exposure of the
co-administered
medicinal products.
Abacavir The co-administration of abacavir and
atazanavir is not expected to significantly alter
the exposure of abacavir.
Didanosine (buffered tablets) Atazanavir, simultaneous administration with Didanosine should be
200 mg/stavudine 40 mg, both ddI+d4T (fasted) taken at the fasted state
single dose Atazanavir AUC: ↓87% (↓92% ↓79%) 2 hours after atazanavir
(atazanavir 400 mg single dose) Atazanavir Cmax : ↓89% (↓94% ↓82%) taken with food. The co-
Atazanavir Cmin : ↓84% (↓90% ↓73%) administration of
stavudine with
Atazanavir, dosed 1 hr after ddI+d4T (fasted) atazanavir is not
Atazanavir AUC: ↔3% (↓36% ↑67%) expected to significantly
Atazanavir Cmax : ↑12% (↓33% ↑18%) alter the exposure of
Atazanavir Cmin : ↔3% (↓39% ↑73%) stavudine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T09:40:00Z · SHA-256 851799f19c7f91ccad410a9396697d8f19a238de0eeb6394755a929570f3b97b · Passage 8e0ed9e032bcc89b98aae9f427eb7df34838c0addf41686dc5b1f4473c96af0c · Zeichen 12174–14370 im Abschnitt
Wechselwirkungen · Atazanavir Viatris (previously Atazanavir Mylan)
Atazanavir Viatris 150 mg hard capsules Atazanavir Viatris 200 mg hard capsules Atazanavir Viatris 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-223179 · Präparat HOS-217134
Atazanavir concentrations were greatly
decreased when co-administered with
didanosine (buffered tablets) and stavudine.
The mechanism of interaction is a reduced
solubility of atazanavir with increasing pH
related to the presence of anti-acid agent in
didanosine buffered tablets.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T09:40:00Z · SHA-256 851799f19c7f91ccad410a9396697d8f19a238de0eeb6394755a929570f3b97b · Passage acf786a270f6014679093ee993ed177323ea9116c0b523f041cd992f23788212 · Zeichen 14407–14897 im Abschnitt
Wechselwirkungen · Atazanavir Viatris (previously Atazanavir Mylan)
Atazanavir Viatris 150 mg hard capsules Atazanavir Viatris 200 mg hard capsules Atazanavir Viatris 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-223180 · Präparat HOS-217134
No significant effect on didanosine and
stavudine concentrations was observed.
Didanosine (enteric coated Didanosine (with food)
capsules) 400 mg single dose Didanosine AUC: ↓34% (↓41% ↓27%)
(atazanavir 300 mg once daily Didanosine Cmax : ↓38% (↓48% ↓26%)
with ritonavir 100 mg once daily) Didanosine Cmin : ↑25% (↓8% ↑69%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): stavudine (HOS-088080) didanosine (HOS-085836) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T09:40:00Z · SHA-256 851799f19c7f91ccad410a9396697d8f19a238de0eeb6394755a929570f3b97b · Passage 1aa63e378737662c086a2feb4455bc23c354c8167ee98227afdbaffdc9b69713 · Zeichen 14934–15308 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.